Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study

Study Overview
=================
Brief Summary
-----------------
Jangzhuo Qinggan prescription and irbesartan in the treatment of essential hypertension(Hepatogastric Damp-heat), randomized, parallel-controlled, multi-center clinical study.

Detailed Description
-----------------
Charged by the five research centers in line with traditional Chinese medicine hepatogastric Damp-heat syndrome 240 cases have hypertension, and overweight, as well as blood lipid disorders or diabetes were randomly divided into Chinese herbal compound Jiangzhuo Qinggan prescription group and western medicine irbesartan group.The treatment groups were compared 4-week step-down and regulation of blood lipids, blood sugar effect.

Official Title
-----------------
Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat), Randomized, Parallel-controlled, Multi-center Clinical Study

Conditions
-----------------
Hypertension, Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consistent with diagnosed hypertension, blood pressure, for 1-2 grade. Aged 18-65 years old. Body mass index (BMI) ≥ 24kg/m2, but <35 kg/m2. Waist circumference ≥ 85cm (male) or waist circumference ≥ 80cm (women). Comply with any of the following 3 : triglyceride (TG) elevated levels of:> 150mg/dl (1.7mmol / l), or has received appropriate treatment; high-density lipoprotein - cholesterol (HDL-C) levels reduced: Men <40mg/dl (0.9mmol / l), women <50mg/dl (1.1mmol / l), or has received appropriate treatment; fasting plasma glucose (FPG) increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or have received appropriate treatment. Hepatogastric Damp-heat syndrome differentiation. To sign informed consent. Exclusion Criteria: Has been used to control lipids, blood sugar drugs, but use the time for those below the 1 month. Nearly 3 months, weight loss ≥ 5%. Suffering from congenital heart disease, rheumatic heart disease, congestive heart failure, unstable angina, and had a myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or off-line clinical significance of arrhythmia. Bilateral renal artery stenosis, solitary kidney, serum creatinine> 133μmol / L . Active liver disease, history of chronic persistent hepatitis, ALT> upper limit of normal. Peptic ulcer or malabsorption syndrome . With insulin-treated diabetes. There is a history of appetite or abuse of laxatives by hyperthyroidism. Pregnancy, pregnancy or breast-feeding women to prepare. For those who are allergic Chinese medicine, allergic people. Mentally ill. Hyperkalemia in patients. Cancer. Occurred within the past 6 months who had a stroke or transient ischemic attack (TIA). Nearly 3 months in patients receiving other clinical studies. Alcohol and / or psychoactive substances, drug abuse and dependency.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| the group of Jiangzhuo Qinggan prescription<br> | |
| the group of irbesartan<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chinese herbs